Table 4.
Sensitivity analysis
| Change in Outcome | CER | ||||
| Parameter | Net Cost | LYG | QALY | Cost/LYG | Cost/QALY |
| Base values | £2,066 | 0.32 | 0.37 | £6,772 | £5,609 |
| Age (mean) | |||||
| 46.5 years | £2,531 | 0.34 | 0.45 | £7,476 | £5,589 |
| 82.5 years | £718 | 0.14 | 0.12 | £5,303 | £5,804 |
| Cost of complications | |||||
| +20% | £1,973 | 0.32 | 0.37 | £6,213 | £5,357 |
| -20% | £2,159 | 0.32 | 0.37 | £6,799 | £5,861 |
| Duration of disease before oral agent prescribed | |||||
| 5 years | £2,101 | 0.27 | 0.33 | £7,680 | £6,320 |
| 10 years | £1,971 | 0.31 | 0.35 | £6,260 | £5,553 |
| Utilities | |||||
| +20% | £2,066 | 0.32 | 0.36 | £6,506 | £5,807 |
| -20% | £2,066 | 0.32 | 0.38 | £6,506 | £5,426 |
| Race | |||||
| 100% Caucasian | £2,105 | 0.31 | 0.36 | £6,686 | £5,771 |
| HbA1c level | |||||
| HbA1c before prescription = 9.4% | £1,782 | 0.37 | 0.42 | £4,784 | £4,287 |
| Metformin = 8.6% | |||||
| Combination = 7.9% | |||||
| HbA1c before prescription = 7.9% | £2,184 | 0.28 | 0.34 | £7,904 | £6,516 |
| Metformin = 7.1% | |||||
| Combination = 6.4% | |||||
| HbA1c upward drift | |||||
| Metformin = 1.5%; Combination = 0% | £1,478 | 0.54 | 0.65 | £2,761 | £2,272 |
| Metformin = 0%; Combination = 0% | £2,307 | 0.28 | 0.31 | £8,336 | £7,338 |
| HbA1c drift delay | |||||
| Metformin = 0 years; Combination = 1 year | £1,987 | 0.35 | 0.41 | £5,715 | £4,870 |
| Discount | |||||
| Cost = 3%; Benefit = 3% | £2,420 | 0.26 | 0.30 | £9,319 | £8,058 |
| Cost = 6%; Benefit = 6% | £2,066 | 0.18 | 0.21 | £11,369 | £9,888 |
| Cost = 6%; Benefit = 0% | £2,066 | 0.39 | 0.46 | £5,237 | £4,500 |